Stay updated on Pembrolizumab and CC-486 in Platinum-resistant Ovarian Cancer Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab and CC-486 in Platinum-resistant Ovarian Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab and CC-486 in Platinum-resistant Ovarian Cancer Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the optimal dose of CC-486 in combination with pembrolizumab for the treatment of platinum-resistant/refractory Epithelial Ovarian Cancer.
    Difference
    0.1%
    Check dated 2024-06-06T14:34:33.000Z thumbnail image
  4. Check
    6 days ago
    No Change Detected
  5. Check
    7 days ago
    No Change Detected
  6. Check
    17 days ago
    Change Detected
    Summary
    The value 'Participation Criteria 6' has been updated to a detailed description of eligibility criteria, explaining that researchers look for people who fit specific descriptions such as general health condition or prior treatments. This change provides more context and examples of what eligibility criteria entail.
    Difference
    49%
    Check dated 2024-05-22T21:11:13.000Z thumbnail image
  7. Check
    39 days ago
    Change Detected
    Difference
    0.7%
    Check dated 2024-04-30T22:21:58.000Z thumbnail image

Stay in the know with updates to Pembrolizumab and CC-486 in Platinum-resistant Ovarian Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab and CC-486 in Platinum-resistant Ovarian Cancer Clinical Trial page.